Note 15 - Segments (Tables)

6 Months Ended

Jun. 30, 2019

Three Months Ended June 30, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	5,940		$	—		$	—		$	5,940
License revenue		9,953			—			—			9,953
Grant and other revenue		196,630			47,569			—			244,199
Total revenue		212,523			47,569			—			260,092
Cost of revenue		238			—			—			238
Research and development expenses		775,462			295,180			—			1,070,642
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			3,062			1,821,812			1,824,874
Depreciation and amortization (2)		—			—			36,726			36,726
Loss from operations (3)		(563,177	)		(250,673	)		(1,858,538	)		(2,672,388	)
Other expense (4)		—			—			(1,590	)		(1,590	)
Income tax benefit		35			16			117			168
Net loss from continuing operations		(563,142	)		(250,657	)		(1,860,011	)		(2,673,810	)
Income from discontinued operations, net of tax		632			—			—			632
Net loss		(562,510	)		(250,657	)		(1,860,011	)		(2,673,178	)
Total assets, net of depreciation and amortization:
United States	$	220,334		$	11,235		$	7,892,312		$	8,123,881
International		6,514			—			—			6,514
Capital expenditures		—			—			—			—

Three Months Ended June 30, 201 8	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	6,665		$	—		$	—		$	6,665
License revenue		257,709			—			—			257,709
Grant and other revenue		156,889			120,864			—			277,753
Total revenue		421,263			120,864			—			542,127
Cost of revenue		35,392			—			—			35,392
Research and development expenses		913,158			229,560			—			1,142,718
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			16,630			1,735,258			1,751,888
Depreciation and amortization (2)		—			—			37,511			37,511
Loss from operations (3)		(527,287	)		(125,326	)		(1,772,769	)		(2,425,382	)
Other expense (4)		—			—			(20,719	)		(20,719	)
Income tax benefit		2,356			560			8,013			10,929
Net loss from continuing operations		(524,931	)		(124,766	)		(1,785,475	)		(2,435,172	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(483,816	)		(124,766	)		(1,785,475	)		(2,394,057	)
Total assets, net of depreciation and amortization:
United States	$	409,769		$	87,751		$	8,139,434		$	8,636,954
International		22,147			—			1,391			23,538
Capital expenditures		—			—			3,165			3,165

Six Months Ended June 30, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	9,090		$	—		$	—		$	9,090
License revenue		9,953			—			—			9,953
Grant and other revenue		232,621			50,052			—			282,673
Total revenue		251,664			50,052			—			301,716
Cost of revenue		6,364			—			—			6,364
Research and development expenses		1,516,045			295,180			—			1,811,225
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			14,776			3,501,835			3,516,611
Depreciation and amortization (2)		—			—			73,505			73,505
Loss from operations (3)		(1,270,745	)		(259,904	)		(3,575,340	)		(5,105,989	)
Other income (4)		—			—			7,122			7,122
Provision for income tax		(177	)		(36	)		(495	)		(708	)
Net loss from continuing operations		(1,270,922	)		(259,940	)		(3,568,713	)		(5,099,575	)
Loss from discontinued operations, net of tax		(2,665	)		—			—			(2,665	)
Net loss		(1,273,587	)		(259,940	)		(3,568,713	)		(5,102,240	)
Total assets, net of depreciation and amortization:
United States	$	220,334		$	11,235		$	7,892,312		$	8,123,881
International		6,514			—			—			6,514
Capital expenditures		—			—			—			—

Six Months Ended June 30, 201 8	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	7,460		$	—		$	—		$	7,460
License revenue		257,709			—			—			257,709
Grant and other revenue		389,325			164,078			—			553,403
Total revenue		654,494			164,078			—			818,572
Cost of revenue		35,710			—			—			35,710
Research and development expenses		1,698,169			443,505			—			2,141,674
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			25,237			3,465,036			3,490,273
Depreciation and amortization (2)		—			—			75,498			75,498
Loss from operations (3)		(1,079,385	)		(304,664	)		(3,540,534	)		(4,924,583	)
Other expense (4)		—			—			(4,259,480	)		(4,259,480	)
Income tax benefit		1,284			363			9,282			10,929
Net loss from continuing operations		(1,078,101	)		(304,301	)		(7,790,732	)		(9,173,134	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(1,036,986	)		(304,301	)		(7,790,732	)		(9,132,019	)
Total assets, net of depreciation and amortization:
United States	$	409,769		$	87,751		$	8,139,434		$	8,636,954
International		22,147			—			1,391			23,538
Capital expenditures		—			—			3,165			3,165